WO2002056708A2 - Zubereitung zur verbesserung der nahrungsverwertung - Google Patents
Zubereitung zur verbesserung der nahrungsverwertung Download PDFInfo
- Publication number
- WO2002056708A2 WO2002056708A2 PCT/EP2002/000370 EP0200370W WO02056708A2 WO 2002056708 A2 WO2002056708 A2 WO 2002056708A2 EP 0200370 W EP0200370 W EP 0200370W WO 02056708 A2 WO02056708 A2 WO 02056708A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- acid
- food
- cis
- trans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to food, food or pharmaceutical preparations which contain conjugated trans / cis octa-decatrienoic acid and to processes for their preparation. Preparations according to the invention preferably contain calendulic acid.
- the invention also relates to the use of the preparations for reducing food intake in humans and animals, and for better food utilization in humans and animals, for changing the body composition, methods for reducing food intake and a kit which contains the preparation according to the invention.
- Fatty acids and triglycerides have a multitude of applications in the food industry, animal nutrition, cosmetics and pharmaceuticals. Depending on whether they are free saturated or unsaturated fatty acids or triglycerides with an increased content of saturated or unsaturated fatty acids, they are suitable for a wide variety of applications. For example, a high proportion of lipids with unsaturated fatty acids and especially with polyunsaturated fatty acids is important for the nutrition of animals and humans, since these e.g. a positive influence on the triglyceride level or cholesterol level in the blood and thus reduce the risk of heart disease. Unsaturated fatty acids are used in various diet foods or medications.
- conjugated unsaturated fatty acids are particularly valuable and sought-after unsaturated fatty acids.
- Conjugated polyunsaturated fatty acids are rather rare compared to other polyunsaturated fatty acids.
- CLA is a collective term for positional and structural isomers of linoleic acid, which are characterized by a conjugated double bond system on the carbon atom 8, 9, 10 or 11. Geometric isomers exist for each of these positional isomers, i.e. cis-cis, trans-cis, cis-trans, trans-trans. Especially C18: 2 cis-9, trans-11 and C18: 2 trans-10, cis-12 CLAs, which are the most biologically active isomers, are of particular interest because they have been shown to be cancer-preventive in animal experiments, anti-arteriosclerotic act and reduce body fat in humans and animals. Commercially, CLAs are mainly sold as free fatty acids.
- CLA CLA-containing fatty acids
- ruminant animals such as cattle (Chin, Journal of Food Composition and Analysis, 5, 1992: 185-197) and sheep, and dairy products have very high CLA concentrations.
- Cattle have 2.9 to 8.9 mg / g fat.
- vegetable oils, margarines and fats from non-ruminant animals have CLA concentrations of only 0.6 to 0.9 mg / g fat.
- Linoleic acid (18: 2); c9, c12)
- conjugated linoleic acid reduces body fat in humans and animals or increases the feed turnover per body weight in animals (WO 94/16690, WO 96/06605, WO 97/46230, WO 97/46118).
- conjugated linoleic acid By administering conjugated linoleic acid, allergies (WO 97/32008), diabetes (WO 99/29317) or cancer can also be positive (Banni, Carcinogenesis, Vol. 20, 1999: 1019-1024, Thompson, Cancer, Res., Vol 57, 1997: 5067-5072).
- Polyunsaturated fatty acids are also added to baby food to "increase the nutritional value" and as essential building blocks that ensure growth and brain development.
- CLA has very far-reaching positive nutritional effects.
- CLA naturally only occurs in significant quantities in ruminants and their products, such as milk, cheese, etc.
- the consumption of meat and milk products has decreased taken to reduce the amount of saturated fat considered unhealthy. At the same time, this also means a reduction in the intake of "healthy" CLA.
- the object of the present invention is therefore to provide an alternative preparation which has nutritionally similar beneficial effects as a preparation which contains CLA.
- the present invention therefore relates to a food, dietary supplement, animal feed or pharmaceutical preparation containing conjugated trans / cis octadecatrienoic acid.
- the present invention is based on the surprising finding that the addition of conjugated trans / cis octadecatrienoic acid, in particular calendulic acid, to food leads to a reduced food intake without a reduction in body weight being observed. That feed conversion is significantly improved when conjugated octadecatrienoic acid is added to the diet.
- octadecatrienoic acid or the term “calendulic acid” includes not only the free acid, but also the salts, and esters and other non-toxic derivatives.
- the term encompasses non-toxic salts or glycerides, especially triglycerides, or ethyl or methyl esters as described below.
- the present invention thus further relates to a method for producing a food, dietary supplement, animal feed or pharmaceutical preparation, which comprises adding a conjugated trans / cis octadecatrienoic acid to the preparation.
- the said trans / cis octadecatrienoic acid preferably has a t10, cl2 configuration.
- said trans / cis octadecatrienoic acid is therefore calendulic acid.
- Calendulic acid is a C18: 3 fatty acid with a t8, tlO, cl2 configuration.
- Calendulic acid is the fatty acid responsible for the observed reduction in food intake and improved food utilization in mice according to the invention when calendula oil is added to the feed, as the comparative experiments in the examples with corn oil show.
- the chemical production of calendulic acid is described in US 3,356,699. Calendula acid comes naturally e.g.
- conjugated trans / cis octadecatrienoic acids can be obtained by chemical modification of oils containing linolenic acid, e.g. from linseed oil, soybean or hemp oil.
- Preparations according to the invention are outstandingly suitable as a food or feed additive, e.g. in diets or on animal fattening.
- calendulic acid can be used to support a diet, e.g. to reduce body weight in humans, which also has an advantageous effect on eating habits.
- the improved utilization of the increased food leads to a reduction in food consumption, which can be particularly advantageous in less developed regions with food shortages or in extreme situations (illnesses, competitive sports).
- a change in body composition in particular a reduction in body fat content, can advantageously be achieved.
- Preparations according to the invention can also be used economically and ecologically advantageously in animal nutrition, in particular for reducing the amount of feed or for reducing the fat content in animals.
- animal nutrition in particular for reducing the amount of feed or for reducing the fat content in animals.
- the conjugated trans / cis octadecatrienoic acid or the calendulic acid is contained in the preparation as calendula oil.
- calendula oil is understood to mean a fatty acid mixture which contains calendula acid.
- the proportion of calendulic acid in the calendula oil is preferably approximately 30%, more preferred is a proportion of 50%, even more preferred is a proportion of 60%, 70%, 80% or 90%. Most preferred is 95% or more.
- the proportion of calendulic acid after saponification of the fatty acids and conversion of the fatty acids to methyl esters can be determined by gas chromatography.
- calendula oil can contain various other saturated or unsaturated fatty acids e.g. Contain linoleic acid, palmitic acid.
- the proportion of the various fatty acids in the calendula oil can fluctuate depending on the production process. Every fatty acid pattern is encompassed by the preparation according to the invention, in particular fatty acid patterns which arise in the production of oil from vegetable material and which contain the calendula oil component mentioned. It is preferred that the calendula oil contains little scatter of different fatty acids or that the number of different fatty acids in the calendula oil is small.
- the preparation mentioned contains further additives.
- additives is understood to mean further additives which are advantageous for nutrition or health, e.g. "Nutrients", “Dietary Additives” or "Active Ingredients”.
- the preparation can contain one or more additives for animal or human nutrition or treatment and can be diluted or mixed therewith. Additives can be administered together with or separately from the feed, food, dietary supplement or pharmaceutical.
- a food, dietary supplement, animal feed or pharmaceutical preparation contains no additives or no amounts of additives that can be considered harmful to animal or human nutrition.
- “Nutrients” are understood to mean additives which are advantageous for the nutrition of humans or animals.
- the preparation according to the invention therefore preferably also contains vitamins, for example vitamins A, B1, B2, B6, B12, C, D3, and / or E, folic acid, nicotinic acid, taurine, carboxylic acids, for example tricarboxylic acids, citrate, isocitrate, trans / cis aconitat, and / or homo-
- the animal feed according to the invention particularly preferably contains inanimate, living and / or reproductive portions of fungi of the genus Mucor, yeasts of the genus Saccharomyces and / or bacteria of Enterobacteriaceae, such as E.
- Bacteria of the genus Bacillus and here of the species Bacillus subtilis are very particularly preferred. Genetically modified and / or transgenic organisms and / or production strains suitable for producing the preparation according to the invention are also included according to the invention. The preceding list is not limiting for the present invention.
- conjugated trans / cis octadecatrienoic acids are administered individually or in combination in feed
- the active compounds are administered as pure substance or mixtures of substances or liquid or solid extracts together with conventional feed ingredients.
- common feed ingredients are: maize, barley, wheat, oats, rye, tritale, sorghum, rice and bran, semolina and flours of these cereals, soybeans, soy products such as soybean meal, rapeseed, rapeseed meal, cottonseed and extraction meal, sunflower, sunflower extract, sunflower meal , Expeller of oilseeds, field beans, peas, gluten, gelatin, tapioca, yeast, single cell protein, fish meal, salts, minerals, trace elements, vitamins, amino acids, oils / fats and the like.
- Advantageous compositions are e.g. in Jeroch, H. et al. Nutrition of farm animals, UTB described.
- the preparation according to the invention can be provided as a powder, granulate, pellet, extrudate with a coating ("coated") and / or as combinations thereof.
- the preparation of the animal feed according to the invention serves, for example, to improve the product properties, such as dust behavior, flow properties, water absorption capacity and storage stability.
- Such preparations are widely known in the prior art. So be in animal nutrition s -d tr tr Di ⁇ TJ tr W Di 2 ⁇ ⁇ -3 W Di Mi Di ⁇ P P- ⁇ ⁇ P- P- ⁇ P- ⁇ P- ⁇ P P- 3: t
- fine or amino acids e.g. preferably essential amino acids or such as e.g. Tyrosine, valine, leucine, threonine, tryptophan, methionine, arginine, histidine or glutamine.
- the amount of conjugated trans / cis octadecatrienoic acid used e.g. Calendulic acid.
- the amount of calendulic acid used can e.g. Represent 0.01% or 0.1% of the amount of fat added to the diet. Also preferred are 0.5%, 1%, 2% or 3%, 5% or 10% calendulic acid. This can also apply to other fatty acids.
- the preparation according to the invention can be used to reduce food intake, change the body composition, and to improve food utilization in humans or animals.
- the preparation according to the invention can be used to reduce the fat content in relation to the body protein content.
- Feed consumption can preferably be reduced by 1% or 2%, even more preferred are 3%, even more preferred are 5%, 10% or more.
- the proportion of fats added is replaced by the conjugated trans / cis octadecatrienoic acid.
- the proportion of conjugated trans / cis octadecatrienoic acid in the added fat is at least 0.1 to 50% by weight, preferably 0.5 to 30% by weight, more preferably 1 to 20% by weight, based on an intake Energy that is 30% fat, that is approx. 70 to 90 g fat / day [according to: reference values for nutrient intake, 2000, German Society for Nutrition, Umschau Braus GmbH publishing company).
- the present invention relates to a method for feeding the preparation according to the invention or for nutrition, with conjugated trans / cis octadecatrienoic acid, in particular calendulic acid, being added to the fat carrier of the diet.
- Calendula oil can be obtained from the seeds of Calendula officinalis (marigold), for example. Table 2 shows that the fatty acid pattern of various calendula oils from calendula seeds in Varies depending on their method of manufacture. Such a variation is considered to be included in the preparation according to the invention.
- Calendula oil can be obtained from plant seeds by pressing, for example, seeds with a high proportion of peel or peeled seeds. The compacts can also be pressed several times.
- Vegetable seeds or other parts of plants can be used from any plant that contains calendulic acid. Whole plants can also be used. It is known that Calendula officialis contains a high proportion of calendula acid and is therefore particularly suitable for the production of calendula oil. Calendulic acid and thus also oil can also be produced synthetically (US 3,356,694).
- Calendulic acid can also be produced by selective introduction of double bonds by Wittich reaction or metathesis.
- calendulic acid can be prepared from oils containing octadecatrienoic acid. These octadecatrienoic acids can be conjugated to propylene glycol at 150 ° C.
- Calendulic acid or its ester can be prepared by isomerization on the double bond of an octadecatrienoic acid in the presence of NaHS0 or KHS0. This reaction can be carried out as described in DE 114 16 90 for dehydrated castor oil (castor oil).
- Calendulic acid can be produced analogously to the production process for CLA from oils containing octadecatrienoic acid: e.g. the isomerization of linoleic acid-containing oils with KOH in propylene glycol is carried out at 150 ° C in one process. Free CLA acids are obtained which contain only small amounts of undesired isomers (EP-839897).
- linoleic acid alkyl esters can be isomerized with catalytic amounts (0.3 to 1%) of base (potassium alcoholate), CLA alkyl esters being obtained in high purity (DE-1156788 and DE-1156789).
- Conjugated fatty acids and their esters can e.g. isomerized on the double bond in the presence of NaHS0 or KHS0, see also DE-1,141,690th
- the conjugated cis / trans octadecatrienoic acid according to the invention produced in plants or microorganisms does not have to be worked up, e.g. by production in plants that are used directly for food or by microorganisms that are used in fermentation processes, such as e.g. in the production of cheese, yogurt, beer.
- the present invention also relates to such plants.
- transgenic crop plants such as Corn, rice, cereals, potatoes or transgenic oil-producing plants that produce calendulic acid, e.g. Linen, sunflowers, olives or plants whose natural calendula content has been increased through classic or transgenic breeding.
- the present invention also relates to a kit which contains the preparation according to the invention.
- the preparation can be packaged in one or more containers.
- the components of the preparation according to the invention in particular calendula oil or calendulic acid, can be packed separately or together in a container of the kit.
- the kit can be used to carry out the method according to the invention and can contain instructions for carrying it out.
- Figure 1 describes the changes in body weight after calendulic acid treatment.
- Figure 2 describes the food intake of female and male mice after treatment with calendulic acid.
- Figure 3 describes the feed conversion of female and male mice after treatment with calendulic acid.
- Figure 4 describes the body fat and protein composition of female mice after calendulic acid treatment. Examples
- the calendula oil used contained approximately 62% calendulic acid (as a triglyceride).
- the fatty acid composition of the calendula oil is shown in Table 2.
- the animals were killed and viscera and organs such as the liver, heart and lungs were removed.
- the empty bodies were frozen in liquid nitrogen, homogenized and the proportion of fat, protein and ash determined using standard methods.
- the body weight gain of the two groups was comparable. However, there were clear differences in the body composition of the animals, especially in terms of body fat content.
- Calendulic acid significantly reduced the fat content in the test animals. The effect was more pronounced in male animals than in female animals:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002557224A JP2004520036A (ja) | 2001-01-17 | 2002-01-16 | 食物利用率を改良するための調製物 |
US10/250,567 US7304089B2 (en) | 2001-01-17 | 2002-01-16 | Preparation for improved dietary utilisation |
EP02715439A EP1353569A2 (de) | 2001-01-17 | 2002-01-16 | Zubereitung zur verbesserung der nahrungsverwertung |
CA002435077A CA2435077A1 (en) | 2001-01-17 | 2002-01-16 | Preparation for improved dietary utilisation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10102050A DE10102050A1 (de) | 2001-01-17 | 2001-01-17 | Zubereitung zur Verbesserung der Nahrungsverwertung |
DE10102050.3 | 2001-01-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002056708A2 true WO2002056708A2 (de) | 2002-07-25 |
WO2002056708A3 WO2002056708A3 (de) | 2002-11-07 |
Family
ID=7670919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/000370 WO2002056708A2 (de) | 2001-01-17 | 2002-01-16 | Zubereitung zur verbesserung der nahrungsverwertung |
Country Status (7)
Country | Link |
---|---|
US (1) | US7304089B2 (de) |
EP (1) | EP1353569A2 (de) |
JP (2) | JP2004520036A (de) |
AR (1) | AR032248A1 (de) |
CA (1) | CA2435077A1 (de) |
DE (1) | DE10102050A1 (de) |
WO (1) | WO2002056708A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006008532A (ja) * | 2004-06-22 | 2006-01-12 | Juntendo | 共役脂肪酸を有効成分とする運動能力改善剤 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10158046A1 (de) * | 2001-11-27 | 2003-06-05 | Basf Ag | Formulierung für den Einsatz in Lebensmitteln, Nahrungsergänzungsmitteln, Futtermitteln, Futterzusatzstoffen, pharmazeutischen und kosmetischen Zubereitungen sowie Verfahren zu deren Herstellung |
WO2005063230A1 (en) * | 2003-12-30 | 2005-07-14 | Universite Laval | Use of conjugated linolenic acids for reducing body fat mass |
JP2005264077A (ja) * | 2004-03-19 | 2005-09-29 | Nisshin Oillio Group Ltd | 共役型トリエン酸含有油脂組成物及びその油脂の製造方法 |
PL1796692T3 (pl) * | 2004-09-09 | 2012-08-31 | Warburton Technology Ltd | Sposób otrzymywania iniekcyjnego roztworu zawierającego pierwiastek śladowy |
CN101098690A (zh) * | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
GB0514463D0 (en) * | 2005-01-31 | 2005-08-17 | Loders Croklaan Bv | Use of pinolenic acid |
EP1874131A2 (de) * | 2005-04-29 | 2008-01-09 | Hill's Pet Nutrition Inc. | Verfahren zur verlängerung des lebens von katzen |
WO2008000440A1 (en) * | 2006-06-27 | 2008-01-03 | Lipid Nutrition B.V. | Use of a polyunsaturated fatty acid compound |
GB0814105D0 (en) * | 2008-08-01 | 2008-09-10 | Springdale Sustainable Develop | Composition for accelerated production of collagen |
JP2013509888A (ja) * | 2009-11-10 | 2013-03-21 | コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 食用に適した脂質を含有する組成物 |
MX348659B (es) * | 2010-11-19 | 2017-05-08 | Centro De Innovacion Biotecnologica A C | Alimentos funcionales con altos contenidos de harina de soya (sbm), almidon y bacillus ssp. |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
CA2947741A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
EP3157936B1 (de) | 2014-06-18 | 2018-10-17 | Thetis Pharmaceuticals LLC | Mineralische aminosäurekomplexe von wirkstoffen |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
WO2016094615A1 (en) * | 2014-12-11 | 2016-06-16 | The Penn State Research Foundation | Medical food for the treatment of malaria and/or iron deficiency |
CA3026264A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators |
CN115462456B (zh) * | 2022-08-19 | 2024-03-15 | 金金 | 一种冬季用肉羊中草药饲料添加剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000011176A2 (en) * | 1998-08-20 | 2000-03-02 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
JP2000336029A (ja) * | 1999-05-28 | 2000-12-05 | Rinoru Oil Mills Co Ltd | 共役リノレン酸を有効成分とする乳癌抑制剤 |
EP1175901A1 (de) * | 1999-04-15 | 2002-01-30 | Kaneka Corporation | Agonisten des peroxisom aktivator-responsiven rezeptors |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1156789B (de) | 1960-04-16 | 1963-11-07 | Brinckmann Harburger Fett | Verfahren zur Umwandlung von Fettsaeureestern einwertiger Alkohole mit isolierten Doppelbindungen (íÀIsolenfettsaeureesterníÂ) in Fettsaeureester mit konjugierten Doppelbindungen (íÀKonjuenfettsaeureesteríÂ) |
SE303998B (de) | 1959-12-02 | 1968-09-16 | Brinckmann Harburger Fett | |
DE1156788C2 (de) | 1959-12-02 | 1973-11-22 | Brinckmann Harburger Fett | Verfahren zur Umwandlung von Fettsaeureestern einwertiger Alkohole mit isolierten Doppelbindungen (íÀIsolenfettsaeureesterníÂ) in Fettsaeureester mit konjugierten Doppelbindungen (íÀKonjuenfettsaeureesteríÂ) |
GB921688A (en) | 1960-09-15 | 1963-03-20 | Nippon Storage Battery Mfg Com | Improvements in and relating to plates for lead-acid batteries |
US3356694A (en) | 1964-08-20 | 1967-12-05 | Syntex Corp | 3-keto-4-methylene derivatives of the androstane and pregnane series and process therefor |
US3356699A (en) | 1965-06-09 | 1967-12-05 | Marvin O Bagby | Alkali isomerization of crepenynic acid to 8, 10, 12-octadecatrienoic acid |
US5428072A (en) | 1992-04-29 | 1995-06-27 | Wisconsin Alumni Research Foundation | Method of increasing the efficiency of feed conversion in animals |
US5554646A (en) | 1992-04-29 | 1996-09-10 | Wisconsin Alumni Research Foundation | Method for reducing body fat in animals |
US5376374A (en) * | 1993-05-24 | 1994-12-27 | Zelaya; Luz M. | Oral rinse composition |
US5814663A (en) | 1994-08-29 | 1998-09-29 | Wisconsin Alumni Research Foundation | Method for maintaining an existing level of body fat |
US5760082C1 (en) | 1994-08-29 | 2001-03-06 | Wisconsin Alumni Res Found | Dietetic foods containing conjugated linoleic acids |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5585400A (en) | 1996-02-27 | 1996-12-17 | Wisconsin Alumni Research Foundation | Methods of attenuating the allergic response in animals |
DE19638729B4 (de) * | 1996-09-13 | 2004-09-23 | Lancaster Group Gmbh | Stabile Mehrphasenemulsion vom Typ 01/W/O2, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
JP3017108B2 (ja) | 1996-10-30 | 2000-03-06 | リノール油脂株式会社 | 共役リノール酸の製造方法 |
WO1999029317A1 (en) | 1997-12-12 | 1999-06-17 | Purdue Research Foundation | Methods and compositions for treating diabetes |
US6197305B1 (en) * | 1998-01-05 | 2001-03-06 | Farmo-Nat Ltd. | Anti-fungal compositions with prolonged activity |
CA2339871A1 (en) | 1998-08-20 | 2000-03-02 | Abbott Laboratories | Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof |
US6444238B1 (en) * | 2000-03-10 | 2002-09-03 | General Cosmetics Corporation | Pain relief composition and method of relieving pain |
WO2001085968A2 (en) * | 2000-05-09 | 2001-11-15 | Bioriginal Food & Science Corp. | Production of conjugated linoleic and linolenic acids in plants |
-
2001
- 2001-01-17 DE DE10102050A patent/DE10102050A1/de not_active Withdrawn
-
2002
- 2002-01-16 CA CA002435077A patent/CA2435077A1/en not_active Abandoned
- 2002-01-16 WO PCT/EP2002/000370 patent/WO2002056708A2/de active Application Filing
- 2002-01-16 EP EP02715439A patent/EP1353569A2/de not_active Withdrawn
- 2002-01-16 JP JP2002557224A patent/JP2004520036A/ja active Pending
- 2002-01-16 US US10/250,567 patent/US7304089B2/en not_active Expired - Fee Related
- 2002-01-17 AR ARP020100155A patent/AR032248A1/es active IP Right Grant
-
2008
- 2008-12-02 JP JP2008306944A patent/JP2009132721A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000011176A2 (en) * | 1998-08-20 | 2000-03-02 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
EP1175901A1 (de) * | 1999-04-15 | 2002-01-30 | Kaneka Corporation | Agonisten des peroxisom aktivator-responsiven rezeptors |
JP2000336029A (ja) * | 1999-05-28 | 2000-12-05 | Rinoru Oil Mills Co Ltd | 共役リノレン酸を有効成分とする乳癌抑制剤 |
Non-Patent Citations (6)
Title |
---|
DHAR P ET AL: "DIETARY EFFECTS OF CONJUGATED OCTADECATRIENOIC FATTY ACID (9 CIS, 11 TRANS, 13 TRANS) LEVELS ON BLOOD LIPIDS AND NONENZYMATIC IN VITRO LIPID PEROXIDATION IN RATS" LIPIDS, CHAMPAIGN, IL, US, Bd. 34, Nr. 2, Februar 1999 (1999-02), Seiten 109-114, XP000973904 ISSN: 0024-4201 * |
DHAR P ET AL: "Nutritional characteristics of oil containing conjugated octadecatrienoic fatty acid" BIOSIS, PREV 199900002659, XP002162410 & ANNALS OF NUTRITION AND METABOLISM, Bd. 42, Nr. 5, Oktober 1998 (1998-10), Seiten 290-296, * |
NUGTEREN D H ET AL: "NATURALLY OCCURRING CONJUGATED OCTADECATRIENOIC ACIDS ARE STRONG INHIBITORS OF PROSTAGLANDIN BIOSYNTHESIS" PROSTAGLANDINS, BUTTERWORTH, STONEHAM, MA, US, Bd. 33, Nr. 3, 1. M{rz 1987 (1987-03-01), Seiten 403-417, XP002063858 ISSN: 0090-6980 * |
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 15, 6. April 2001 (2001-04-06) & JP 2000 336029 A (RINORU OIL MILLS CO LTD), 5. Dezember 2000 (2000-12-05) * |
TAKAGI T ET AL: "OCCURRENCE OF MIXTURES OF GEOMETRICAL ISOMERS OF CONJUGATED OCTADECATRIENOIC ACIDS IN SOME SEED OILS: ANALYSIS BY OPEN-TUBULAR GAS LIQUID CHROMATOGRAPHY AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY" LIPIDS, CHAMPAIGN, IL, US, Bd. 16, Nr. 7, Juli 1981 (1981-07), Seiten 546-551, XP000973303 ISSN: 0024-4201 * |
YURAWECZ ET AL.: "Estimation of Conjugated Octadecatrienes in Edible Fats and Oils" JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY., Bd. 70, Nr. 11, November 1993 (1993-11), Seiten 1093-1099, XP002207591 AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN., US ISSN: 0003-021X * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006008532A (ja) * | 2004-06-22 | 2006-01-12 | Juntendo | 共役脂肪酸を有効成分とする運動能力改善剤 |
Also Published As
Publication number | Publication date |
---|---|
DE10102050A1 (de) | 2002-07-18 |
AR032248A1 (es) | 2003-10-29 |
JP2009132721A (ja) | 2009-06-18 |
CA2435077A1 (en) | 2002-07-25 |
WO2002056708A3 (de) | 2002-11-07 |
EP1353569A2 (de) | 2003-10-22 |
US20040047894A1 (en) | 2004-03-11 |
US7304089B2 (en) | 2007-12-04 |
JP2004520036A (ja) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1353569A2 (de) | Zubereitung zur verbesserung der nahrungsverwertung | |
AU2001273028B2 (en) | Improved methods of incorporating polyunsaturated fatty acids in milk | |
US5770247A (en) | Method of increasing the CLA content of cow's milK | |
US6042869A (en) | Bulk animal feeds containing conjugated linoleic acid | |
DE60011251T2 (de) | Verfahren zur selektiven veränderung des körperfettgehaltes, der futterverwendung oder der gewichtszunahme | |
DE4327310C2 (de) | Futtermittelzusammensetzung für Milchkühe und deren Verwendung zur Erzeugung von mit n-3-Fettsäuren angereicherter Milch | |
EP4151090A1 (de) | Herstellung eines zusammengesetzten pansengeschützten mehrfach ungesättigten fettsäurepulvers und verwendung davon | |
DE10158046A1 (de) | Formulierung für den Einsatz in Lebensmitteln, Nahrungsergänzungsmitteln, Futtermitteln, Futterzusatzstoffen, pharmazeutischen und kosmetischen Zubereitungen sowie Verfahren zu deren Herstellung | |
MXPA06013990A (es) | Sintesis de sal de metal monovalente y divalente de acido graso polinsaturado. | |
US20200268005A1 (en) | Pelleted ruminant feed enriched with rumen-available ingredients | |
EP1314358A1 (de) | Antimikrobielle Zusammensetzung für Tiere | |
DE2352797A1 (de) | Ernaehrungszusatz | |
US6432469B1 (en) | Bulk animal feeds containing conjugated linoleic acid | |
EP1373182A1 (de) | Konjugierte ungesättigte glyceridgemische und verfahren zur ihrer herstellung | |
Bauman | Conjugated linoleic acid (CLA) and milk fat: A Good News Story | |
CN1215776C (zh) | 提高ω-3脂肪酸降低胆固醇蛋禽类饲料添加剂 | |
JPS61216658A (ja) | 生理活性物質を含有する卵、肉、および乳 | |
KR20040051096A (ko) | 동충하초 포함 돼지사료용 조성물 | |
DE1767860C3 (de) | ||
WO2001010424A2 (de) | Verringerung von cholesterinoxiden durch n-3-pufa und vitamin e | |
Bartkovský et al. | Effect of feeding of 10% prefermented feed on fatty acid profile and oxidation changes in chicken breast meat | |
DE19930221A1 (de) | Nahrungsergänzungsprodukt zur Ergänzung der alltäglich benötigten Basisnährstoffe | |
Noviandi et al. | Protected fat-protein response in the diet to fatty acid profile of rumen fluid | |
CN111631309A (zh) | 生产含有牡丹亚油酸牛奶的产奶牛日粮及制备方法 | |
CN111011648A (zh) | 一种围栏罗非鱼养殖饲料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002715439 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10250567 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002557224 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2435077 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002715439 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |